Analysts Set Retrophin Inc (NASDAQ:RTRX) Target Price at $44.50

Shares of Retrophin Inc (NASDAQ:RTRX) have been given a consensus recommendation of “Buy” by the ten analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $44.50.

RTRX has been the subject of several recent analyst reports. William Blair reaffirmed a “buy” rating on shares of Retrophin in a research note on Friday, July 5th. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Barclays assumed coverage on GENFIT S A/ADR in a report on Monday, April 22nd. They set an “overweight” rating and a $55.00 price target on the stock. BidaskClub lowered Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Canaccord Genuity reissued a “speculative buy” rating and issued a GBX 70 ($0.91) target price on shares of Bacanora Lithium in a research report on Monday, July 1st.

NASDAQ RTRX traded up $0.13 during trading on Friday, hitting $21.14. The stock had a trading volume of 8,447 shares, compared to its average volume of 437,164. Retrophin has a 12 month low of $17.53 and a 12 month high of $33.00. The firm has a market cap of $872.31 million, a P/E ratio of -8.32 and a beta of 0.93. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.57 and a quick ratio of 4.52. The company has a 50-day moving average price of $19.58.

Retrophin (NASDAQ:RTRX) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.41). The company had revenue of $39.57 million for the quarter, compared to the consensus estimate of $41.40 million. Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. The business’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.14) earnings per share. Sell-side analysts expect that Retrophin will post -3.02 EPS for the current year.

In other news, COO Neil F. Mcfarlane sold 1,968 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $18.25, for a total transaction of $35,916.00. Following the transaction, the chief operating officer now directly owns 27,972 shares of the company’s stock, valued at approximately $510,489. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider William E. Rote sold 1,625 shares of the stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $17.77, for a total value of $28,876.25. The disclosure for this sale can be found here. Insiders sold a total of 10,819 shares of company stock worth $194,503 in the last 90 days. 4.32% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers lifted its position in shares of Retrophin by 51.4% during the fourth quarter. Rhumbline Advisers now owns 55,247 shares of the biopharmaceutical company’s stock worth $1,250,000 after purchasing an additional 18,748 shares in the last quarter. Northern Trust Corp grew its position in shares of Retrophin by 0.6% during the fourth quarter. Northern Trust Corp now owns 760,496 shares of the biopharmaceutical company’s stock worth $17,210,000 after acquiring an additional 4,277 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Retrophin by 6.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,154,859 shares of the biopharmaceutical company’s stock worth $26,134,000 after acquiring an additional 67,834 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Retrophin by 5.3% during the fourth quarter. Geode Capital Management LLC now owns 483,083 shares of the biopharmaceutical company’s stock worth $10,932,000 after acquiring an additional 24,468 shares during the last quarter. Finally, Broadfin Capital LLC grew its position in Retrophin by 8.3% in the 4th quarter. Broadfin Capital LLC now owns 1,016,114 shares of the biopharmaceutical company’s stock valued at $22,995,000 after buying an additional 77,900 shares in the last quarter.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Read More: Cash Asset Ratio

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.